Advertisement Cardio3 wins GMP certification for new production facilities in Belgium - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Cardio3 wins GMP certification for new production facilities in Belgium

The Cardio3 BioSciences (C3BS), a biotechnology company, has received Good Manufacturing Practice (GMP) Certification for its new production facilities in Mont-Saint-Guibert.

Certification was granted by the Federal Agency for Medicines and Health Products (FAMHP) in Belgium.

The Mont-St-Guibert production facilities are used in the manufacture and testing of Cardio3 BioSciences’ C3BS-CQR-1, a regenerative therapy currently in development for the treatment of heart failure, the company said.

C3BS CEO Christian Homsy said: "Gaining GMP certification from the health authorities is also a key step for Cardio3 BioSciences ahead of our planned Phase III trial for C3BS-CQR-1, a product we believe offers a potentially revolutionary new approach for the treatment of heart failure, one of the world’s most significant unmet medical needs."